Navigating Growth: A Deep Dive into the Alger Small Cap Focus Fund's Q1 2026 Performance

Strategic Sector Allocations in Early 2026

During the initial quarter of 2026, the fund's investment strategy heavily favored specific sectors. The most significant portfolio allocations were directed towards the Health Care and Industrials sectors, reflecting a deliberate focus on these areas for potential growth.

Key Contributors to Fund Performance

Several companies played a crucial role in enhancing the fund's performance. Among the top positive contributors were RBC Bearings Incorporated, Cognex Corporation, and Nebius Group, each demonstrating strong results that bolstered the portfolio's overall returns.

Factors Influencing RBC Bearings' Success

RBC Bearings' impressive performance can be attributed to several driving forces. A notable increase in commercial aircraft production, a robust aerospace aftermarket, and a rise in defense spending collectively contributed to its strong showing. These factors, combined with an early recovery in industrial markets, supported expanding profitability and robust free cash flow for the company.

Cognex Corporation's Path to Margin Expansion

Cognex is strategically positioned for future margin growth by divesting from less profitable ventures and concentrating on opportunities with higher margins. The company has also initiated a significant cost reduction program, which is expected to considerably improve its margins in the upcoming year.

Nebius Group's Growth in AI Infrastructure

Nebius Group is experiencing substantial growth, underpinned by its advancements in AI infrastructure. The company has secured a major multi-year contract with a leading AI hyperscaler and reported dramatic year-over-year revenue increases. Achieving positive adjusted earnings further strengthens its position to capitalize on the ongoing expansion of AI computing infrastructure.

Principal Detractors from Fund Performance

Conversely, certain holdings negatively impacted the fund's performance. The primary detractors included Repligen Corporation, Agilysys, Inc., and GeneDx Holdings Corp., which experienced challenges during the quarter.